Haoneng(SH:603809) Zheng Quan Shi Bao Wang·2025-09-14 08:41Group 1 - The core viewpoint of the articles highlights the significant increase in merger and acquisition (M&A) activities in the Shanghai Stock Exchange, with 14 projects registered this year, showing several times growth compared to last year [1][2] - The newly registered projects focus on resource integration within their main business areas, with Aikodi acquiring 71% of Zhuoerbo's shares and raising up to 520 million yuan in supporting funds, enhancing its investment value [1] - Qianjin Pharmaceutical announced its acquisition of 28.92% of Qianjin Xiangjiang Pharmaceutical and 68% of Qianjin Xieli Pharmaceutical, increasing its stake in these subsidiaries, which are key profit sources for its Western medicine segment [1] Group 2 - The effects of the "Eight Policies for the Sci-Tech Innovation Board" and "Six Policies for M&A" are becoming evident, with 27 M&A projects accepted and 15 approved by the restructuring committee since 2025, surpassing last year's total [2] - The Shanghai Stock Exchange is improving the efficiency of restructuring reviews, exemplified by Aikodi's project taking about three months from acceptance to registration [2] - Innovative and exemplary M&A cases are emerging, such as Sairisi and Sanyou Medical enhancing business integration, and major brokerages like Guotai Junan merging with Haitong Securities [2]